The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The impact of secondary AML mutations on the prognosis of patients with NPM1-mutated AML
Onyee Chan, MD, Moffitt Cancer Center, Tampa, FL, discusses the findings from a retrospective multi-center study examining the impact of secondary mutations on the prognosis of patients with NPM1-mutated acute myeloid leukemia (AML). Overall, it was found that patients with AML who harbored both NPM1 and secondary mutations had a shorter overall survival (OS) compared to patients who only harbored the NPM1 mutation. Dr Chan further highlights data from a subset analysis which investigated measurable residual disease (MRD) status and the impact of secondary mutations on favorable ELN risk groups. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Syntrix Pharmaceuticals: Research Funding.
